A few nucleotide polymorphisms are sufficient to recruit nuclear factors differentially to the intron 1 of HPV-16 intratypic variants

Virus Research

Volumn 166, Issue 1-2, 2012, Pages 43-53

  López Urrutia, Eduardo ^a   Valdés, Jesús ^a   Bonilla Moreno, Raúl ^a   Martínez Salazar, Martha ^b   Martínez Garcia, Martha ^c   Berumen, Jaime ^d,e   Villegas Sepúlveda, Nicolás ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

C33 A cells; E6 E7 splicing; HPV 16 variants; SNPs; Splicing factors

Indexed keywords

NUCLEAR FACTOR;

ARTICLE; GENETIC VARIABILITY; HUMAN PAPILLOMAVIRUS TYPE 16; INTRON; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL GENETICS; VIRUS TRANSCRIPTION;

CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTRONS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; POLYMORPHISM, GENETIC; REPRESSOR PROTEINS; RNA SPLICING; RNA-BINDING PROTEINS; TRANSCRIPTION, GENETIC;

HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84860634152     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.02.026     Document Type: Article

References (51)

1. Allemand E., Batsché E., Muchardt C. Splicing, transcription, and chromatin: a ménage à trois. Curr. Opin. Genet. Dev. 2008, 18:145-151.
2. Asadurian Y., Kurilin H., Lichtig H., Jackman A., Gonen P., Tommasino M., Zehbe I., Sherman L. Activities of human papillomavirus 16 E6 natural variants in human keratinocytes. J. Med. Virol. 2007, 79:1751-1760.
3. Baker C.C., Phelps W.C., Lindgren V., Braun M.J., Gonda M.A., Howley P.M. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 1987, 61:962-971.
4. Batcshé E., Yaniv M., Muchrardt C. The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat. Struct. Mol. Biol. 2006, 13:22-29.
5. Chan S-Y., Ho L., Ong C-K., Chow V., Drescher B., Dürst M., ter Meulen J., Villa L., Luande J., Mgaya H.N., Bernard H-U. Molecular variants of human papillomavirus type 16 from our continent suggest ancient pandemic spread of the virus and its coevolution with humankind. J. Virol. 1992, 66:2057-2066.
6. Choi E-Y., Pintel D. Splicing of the large intron present in the nonstructural gene of minute virus of mice is governed by TIA-1/TIAR binding downstream of the nonconsensus donor. J. Virol. 2009, 83:6306-6311.
7. De la Rosa-Ríos M.A., Martínez-Salazar M., Martínez-Garcia M., Gonzalez-Bonilla C., Villegas-Sepúlveda N. The intron I of HPV16 has a suboptimal branch point at a guanosine. Virus Res. 2006, 118:46-54.
8. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.-U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324:17-27.
9. Del Moral-Hernández O., López-Urrutia E., Bonilla-Moreno R., Martínez-Salazar M., Aréchaga-Ocampo E., Berumen J., Villegas-Sepúlveda N. The HPV-16 E7 oncoprotein is expressed mainly from the unspliced E6/E7 transcript in cervical carcinoma C33-A cells. Arch. Virol. 2010, 155:1959-1970.
10. Dyhr-Mikkelsen H., Kjems J. Inefficient spliceosome assembly and abnormal branch site selection in splicing of an HIV-1 transcript in vitro. J. Biol. Chem. 1995, 270:24060-24066.
11. Förch P., Puig O., Kedersha N., Martínez C., Granneman S., Séraphin B., Anderson P., Valcárcel J. The apoptosis-promoting factor TIA-1 is a regulator of alternative pre-mRNA splicing. Mol. Cell 2000, 6:1089-1098.
12. Förch P., Puig O., Martinez C., Seraphin B., Valcarcel J. The splicing regulator TIA-1 interacts with U1-C to promote U1 snRNP recruitment to 5' splice sites. EMBO J. 2002, 21:6882-6892.
13. Grosso A.R., Martins S., Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep. 2008, 9:1087-1093.
14. Harris D., Zhang Z., Chaubey B., Pandey V.N. Identification of the cellular factors associated with the 3'-nontranslated region of the hepatitis c virus genome. Mol. Cell Proteomics 2006, 5:1006-1018.
15. Hawley-Nelson P., Voudsen K.H., Hubbert N.L., Lowy D.R., Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalizate human foreskin keratinocytes. EMBO J. 1989, 8:3905-3910.
16. Hiller M., Zhang Z., Backofen R., Stamm S. Pre-mRNA secondary structures influence exon recognition. PLOS Genet. 2007, 3:2147-2155.
17. Ho L., Chan S-Y., Chow V., Chong T., Tay S-K., Villa L.L., Bernard H-U. Sequence variants of human papillomavirus type 16 in clinical samples permit verification and extension of epidemiological studies and construction of a phylogenetic tree. J. Clin. Microbiol. 1991, 29:1765-1772.
18. Izquierdo J.M., Majós N., Bonna S., Martínez C., Castelo R., Guigó R., Bilbao D., Valcárcel J. Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol. Cell 2005, 19:475-484.
19. Jeon S., Lambert P.F. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of the E6 and E7 mRNAs: Implications for cervical carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 1995, 92.:1654-1658.
20. Le Guiner C., Lejeune F., Galiana D., Kister L., Breathnach R., Stévenin J., Del Gatto-Konczak F. TIA-1 and TIAR activate splicing of alternative exons with weak 5' splice sites followed by a U-rich stretch on their own pre-mRNAs. J. Biol. Chem. 2001, 276:40638-40646.
21. Lichtig H., Algrisi M., Botzer L.E., Abadi T., Verbitzky Y., Jackman A., Tommasino M., Zehbe I., Sherman L. HPV16 natural variants exhibit different activities in funcional assays relative to the carcinogenic potential of E6. Virology 2006, 350:216-227.
22. Lukong K.E., Richard S. Sam68, the KH domain-containing superSTAR. Biochim. Biophys. Acta 2003, 1653:73-86.
23. McFarlane M., Graham S.V. Human papillomavirus regulation of SR proteins. Biochem. Soc. Trans. 2010, 38:1116-1121.
24. McNicol P., Guijon F., Wayne S., Hidajat R., Paraskevas M. Expression of human papillomavirus type 16 E6-E7 open reading frame varies quantitatively in biopsy tissue from different grades of cervical intraepithelial neoplasia. J. Clin. Microbiol. 1995, 33:1169-1173.
25. Milligan S.G., Veerapraditsin T., Ahamet B., Mole S., Graham S.V. Analysis of novel human papillomavirus type 16 late mRNAs in differentiated W12 cervical epithelial cells. Virology 2007, 360:172-181.
26. Münger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 1989, 63:4417-4421.
27. Pagani F., Baralle F.E. Genomic variants in exons and introns: identifying the splicing spoilers. Nat. Rev. Genet. 2004, 5:389-396.
28. *I early mRNA is coupled to EGF signaling via Erk1/2 activation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7006-7011.
29. Shai A., Brake T., Somoza C., Lambert P.F. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res. 2007, 67:1626-1635.
30. Schellenberg M.J., Ritchie D.B., MacMillan A.M. Pre-mRNA splicing: a complex picture in higher definition. Trends Biochem. Sci. 2008, 33:243-246.
31. Sharp P.A. Split genes and RNA splicing. Cell 1994, 77:805-816.
32. Shirasawa H., Tanzawa H., Matsunaga T., Simizu B. Quantitative detection of spliced E6-E7 transcripts of human papillomavirus type 16 in cervical premalignant lesions. Virology 1991, 184:795-798.
33. Singh R., Valcárcel J. Building specificity with nonspecific RNA-binding proteins. Nat. Struct. Mol. Biol. 2005, 12:645-653.
34. Smotkin D., Prokoph H., Wettstein F.O. Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J. Virol. 1989, 63:1441-1447.
35. Stacey S.N., Jordan D., Snijders P.J.F., Mackett M., Walboomers J.M.M., Arrand J.R. Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. J. Virol. 1995, 69:7023-7031.
36. Stöppler M.C., Ching K., Stöppler H., Clancy K., Schlegel R., Icenogle J. Natural variants of the human papillomavirus type 16 E6 differ in their abilities to alter keratinocyte differetiation and to induce p53 degradation. J. Virol. 1996, 70:6987-6993.
37. Tisserant A., König H. Signal-regulated pre-mRNA occupancy by the general splicing factor U2AF. PLOS One 2008, 3:e1418.
38. Underhill C., Qutob M.S., Yee S.P., Torchia J. A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor Kap-1. J. Biol. Chem. 2000, 275:40463-40470.
39. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J.F., Peto J., Meijer C.J.L.M., Muñoz N. Human papillomavirus is necessary cause of invasive cercal cancer worldwide. J. Pathol. 1999, 189:12-19.
40. Wang X.G., Revskaya E., Bryan R.A., Strickler H.D., Burk R.D., Casadevall A., Dadachoca E. Treating cancer as an infectious disease-viral antigens as novel targeting for treatment and potential prevention of tumors of viral etiology. Plos one 2007, 10:e1114.
41. Xi L.F., Koutsky L.A., Hildesheim A., Galloway D.A., Wheeler C.M., Winer R.L., Ho J., Kiviat N.B. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidem. Biomar. 2007, 16:4-10.
42. Yamada T., Manos M.M., Peto J., Greer C.E., Muñoz N., Bosch F.X., Wheeler C.M. Human papillomavirus type 16 sequence variation in cervical cancers: A worldwide perspective. J. Virol. 1997, 71:2463-2472.
43. Zabolontny J.M., Krummenacher C., Fraser N.W. The herpes simplex virus type 1 2.0 kilobase latency-associated transcript is a stable intron which branches at a guanosine. J. Virol. 1997, 71:4199-4208.
44. Zehbe I., Voglino G., Delius H., Wilander E., Tommasino M. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 1998, 352:1441-1442.
45. Zehbe I., Wilander E., Delius H., Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 1998, 58:829-833.
46. Zehbe I., Richard C., De Carlo C.A., Shai A., Lambert P.F., Lichtig H., Tommasino M., Sherman L. Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis. Virology 2009, 383:69-77.
47. Zhao X., Oberg D., Rush M., Fay J., Lambkin H., Schwartz S. A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstfF64, hnRNP C1/C2, and polypyrimidine tract binding protein. J. Virol. 2005, 79:4270-4288.
48. Zhu H., Hasman R.A., Young K.M., Kedersha N.L., Lou N.L. U1 snRNP-dependent function of TIAR in the regulation of alternative RNA processing of the human calcitonin/CGRP pre-mRNA. Mol. Cell Biol. 2003, 23:5959-5971.
49. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003, 31:3406-3415.
50. Zuna R.E., Moore W.E., Shanesmith R.P., Dunn S.T., Wang S.S., Schiffman M., Blakey G.L., Teel T. Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population. Int. J. Cancer 2009, 125:2609-2613.
51. zur Hausen H. Papillomairuses-to vaccination and beyond. Biochemistry (Mosc.) 2008, 73:498-503.